Analysts Issue Forecasts for MiMedx Group Q1 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Equities researchers at Northland Capmk issued their Q1 2025 earnings estimates for MiMedx Group in a report released on Friday, December 27th. Northland Capmk analyst C. Byrnes expects that the company will post earnings per share of $0.05 for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.09 EPS.

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Up 0.3 %

NASDAQ:MDXG opened at $9.42 on Monday. The company’s fifty day moving average price is $8.35 and its 200-day moving average price is $7.17. The firm has a market capitalization of $1.38 billion, a P/E ratio of 17.13 and a beta of 1.98. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MDXG. Isthmus Partners LLC raised its stake in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after buying an additional 91,714 shares in the last quarter. Blue Trust Inc. bought a new stake in shares of MiMedx Group during the 3rd quarter worth $30,000. Point72 Asset Management L.P. acquired a new position in MiMedx Group in the 2nd quarter worth approximately $40,000. Point72 DIFC Ltd lifted its position in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after purchasing an additional 4,275 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of MiMedx Group during the 3rd quarter worth about $64,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.